GET DAILY SIGNALSWhy Is Rigel Pharmaceuticals (RIGL) Stock Down -12.67% Today?
Key Takeaways
- RIGL shares tumbled 12.67% to $39.92 in early trading, extending a post-earnings selloff.
- The primary catalyst is a third-quarter earnings miss, with diluted EPS of $0.65 falling short of the roughly $0.87 consensus.
- Secondary drivers include decelerating TAVALISSE growth, a decline in GAVRETO sales, and margin pressure from VEPPANU launch spending.
- The move reflects company-specific fundamentals rather than broad biotech weakness, as investors reassess the commercial outlook.
- Traders are now watching VEPPANU launch execution and December ASH data for the R289 pipeline program.
- For more detail on valuation and analyst views, explore Price Targets, Earnings, and Forecast pages.
- To see AI-driven trading strategies for this and other symbols, visit Trending AI Robots.
Opening Summary
Rigel Pharmaceuticals, Inc. (RIGL) is a South San Francisco-based biotechnology company developing and commercializing therapies for hematologic disorders and cancer, with a portfolio that includes TAVALISSE, REZLIDHIA, GAVRETO, and the newly launched VEPPANU. Shares of RIGL fell sharply in Wednesday's session, dropping 12.67% to $39.92 from the prior close of $45.71. The decline extended losses that began after the company reported third-quarter 2026 results, as investors focused on an earnings miss and slowing momentum in the legacy product portfolio despite better-than-expected revenue.
Earnings Miss Drives the Selloff
The immediate market reaction centered on the bottom line. Rigel posted third-quarter diluted earnings per share of $0.65, well below the consensus estimate near $0.87 and down 55.5% from the year-ago period. While total revenue of $80.89 million beat expectations of roughly $78 million and grew 16.5% year over year, the earnings shortfall reflected a sharp rise in costs. Total costs and expenses climbed to $63.8 million from $41.0 million a year earlier, as research and development spending more than doubled to $18.3 million and selling, general, and administrative expenses rose to $34.7 million to support the VEPPANU commercial launch. The combination of higher spending and compressed margins overshadowed the record top-line result, prompting investors to sell the stock.
TAVALISSE Slowdown and Portfolio Pressure
Beneath the headline numbers, the composition of growth added to the bearish tone. Net product sales reached a record $72.3 million, up 13% year over year, but the underlying drivers diverged. TAVALISSE, the company's foundational product, grew just 3% to $46.0 million, a marked deceleration from 18% growth in the second quarter and a sequential decline despite what management described as record demand. GAVRETO sales fell 11% to $9.8 million, while REZLIDHIA was a relative bright spot, rising 20% to $9.9 million. The slowdown in the mature portfolio raises questions about how quickly the base business can fund the company's shift toward its newer growth engines.
VEPPANU Launch and Guidance Trade-Offs
VEPPANU, the first FDA-approved PROTAC therapy for ER-positive, HER2-negative ESR1-mutated metastatic breast cancer, generated $6.6 million in net product sales over roughly six weeks of availability — a strong early signal with more than 100 patients and clinics shipped and encouraging refill rates. However, management tempered near-term visibility by trimming 2026 net product sales guidance, excluding VEPPANU, to $255–260 million from $255–265 million, while narrowing total revenue guidance upward to $290–295 million on higher expected contract revenue. The company also indicated it would not guide VEPPANU until 2027 and would stop disclosing detailed launch metrics, making the next several quarters harder to underwrite. Cash and short-term investments fell to $99.3 million from $155.0 million, adding a layer of balance-sheet scrutiny.
Market Context and Trading Activity
Trading in RIGL was notably heavy around the earnings release, with volume running well above the stock's recent daily average as the report and subsequent conference call circulated. The decline was largely idiosyncratic, driven by company-specific fundamentals rather than a broad rotation out of the biotechnology sector. The stock's slide pushed it decisively below the $45 area, which had acted as a near-term support zone following the prior session's drop, and reinforced a negative technical tone heading into the second half of the week.
What Comes Next for RIGL
Investors will now focus on execution of the VEPPANU launch and whether the early demand trajectory translates into durable prescription growth into 2027. A key near-term catalyst is the American Society of Hematology (ASH) meeting in December, where Rigel plans to present updated Phase 1b data, including preliminary efficacy results, for its R289 dual IRAK1/4 inhibitor in lower-risk myelodysplastic syndromes. The company remains on track to select a recommended Phase 2 dose by the end of 2026 and expects to initiate a registrational program next year. Risks include continued deceleration in TAVALISSE, potential gross-to-net and inventory variability in product sales, and the inherent uncertainty of clinical development. Management has reiterated its expectation for positive net income for full-year 2026, but the path to restoring investor confidence will likely depend on demonstrating that the launch investments are producing scalable returns.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI-powered trading bots that are performing strongly under current market conditions. Tickeron offers hundreds of AI trading bots covering thousands of tickers, with bots that vary by strategy, timeframe, performance metrics, and traded symbols. Only the strongest performers are featured in this section, giving traders a way to explore data-driven approaches across a wide range of stocks and market environments. Explore the Trending AI Robots page to see which strategies are currently leading.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
RIGL sees MACD Histogram crosses below signal line
RIGL saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 05, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 38 instances where the indicator turned negative. In 36 of the 38 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 50 of 59 cases where RIGL's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 85%.
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on RIGL as a result. In 63 of 75 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.
RIGL moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RIGL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
Bullish Trend Analysis
Following a +1.78% 3-day Advance, the price is estimated to grow further. Considering data from situations where RIGL advanced for three days, in 226 of 276 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
RIGL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 174 of 210 cases where RIGL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 83%.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 12 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. RIGL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 71 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.007) is normal, around the industry mean (2.788). P/E Ratio (2.565) is within average values for comparable stocks, (-0.376). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.911) among similar stocks. P/S Ratio (3.146) is also within normal values, averaging (440.869).
The Tickeron Profit vs. Risk Rating rating for this company is 71 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RIGL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 92 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a clinical-stage drug development company that discovers and develops novel, small-molecule drugs
Industry Biotechnology
Advertisement